Actress Samantha Ruth Prabhu, who has been on a break and has been treating her fans with beautiful pictures from her holiday, has refuted the claims of her taking Rs 25 crore from a Telugu superstar for her treatment of Myositis. The actress also called out the media for false reportage. Myositis is a medical condition causing inflammation in muscles. Weakness, swelling, and pain are the most common Myositis symptoms. In October last year, the actress shared on her social media that she was diagnosed with Myositis a few back and that the fight against the disease is taking longer than she expected. Samantha Ruth Prabhu Denies Reports of Taking Rs 25 Crore for Myositis Treatment From Telugu Superstar (View Post).
On Saturday (August 5), the actress took to the stories section of her Instagram and penned a note in which she outrightly denied taking any kind of financial help. She wrote, “Rs 25 crores to treat Myositis!? Someone got you a pretty bad deal. I am glad I am only spending the smallest fraction of that. And, I don’t think I was paid in marbles for all the work I’ve done in my career”. Samantha Ruth Prabhu Becomes a Peacemaker for Two Adorable Puppies, Internet Is in Love (View Pic).
Samantha Ruth Prabhu Slams False Reports:
She further mentioned that she is capable of taking care of herself and her medical expenses given her work in the industry during all these years. “So, I can easily take care of myself. Thank you. Myosotis is a condition thousands suffer from. Let’s please be responsible with the information we put out regarding the treatment,” she added.
After wrapping up the Indian counterpart of the web series Citadel, as well as her Telugu film Kushi, Samantha is taking a break from acting for at least one year. During this period, she would primarily focus on her health, and undergo treatment for the autoimmune condition Myositis in the US.
(The above story first appeared on LatestLY on Aug 05, 2023 06:05 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).